MedTrace Logo

Effects of Phosphate Binding With Sevelamer in Stage 3 Chronic Kidney Disease

NCT00806481 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2011-11-23

No results posted yet for this study

Summary

The purpose of this study is to determine whether lowering phosphate in patients with early chronic kidney disease with the phosphate binder sevelamer has beneficial effects on cardiovascular structure and function.

Conditions

Interventions

DRUG

Sevelamer carbonate

Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks

DRUG

Placebo

Treatment group: treatment with tablets of placebo three times daily for 36 weeks

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    collaborator INDUSTRY

  • University Hospital Birmingham NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Charles J Ferro, BSc (Hons), MBChB, FRCP, MD · University Hospital Birmingham NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00806481 on ClinicalTrials.gov